Essity restructuring 2026

The leadership read

Essity's strategic review of Consumer Tissue commits the company to a defined decision window on a business that competes primarily on price, scale, and private-label margin, a structurally difficult position for a health and hygiene group increasingly orienting around higher-margin professional and medical segments. The review doesn't just evaluate a sale; it forces Essity to run two parallel operating logics simultaneously, one managing the Consumer Tissue business as a going concern, the other preparing it for separation, partnership, or divestiture. That is a materially different management load than maintaining a stable portfolio, and it falls particularly hard on regional operations where the business sits inside integrated commercial and supply-chain structures. This is one of twelve restructuring signals we have tracked across sectors in the last 90 days. The comparable moves most relevant here are directional rather than sector-identical: Standard Chartered divesting its Singapore consumer lending book to refocus on higher-margin activity, and ITV Studios preparing for a structural separation amid declining revenues. The consistent shape across all three is portfolio simplification under margin pressure, businesses shedding consumer-facing, commoditised units to protect group returns. Companies executing this kind of portfolio separation consistently face concentrated demand in transaction-side commercial leadership, carve-out operations capability, and the cross-functional coordination required to maintain customer and supply-chain continuity through an ownership transition. The ANZ geography adds complexity where regional structures are often deeply integrated with global systems rather than cleanly separable.